Clinical significance of atypical glandular cells in Pap tests: experience of a gynecologic oncology center in 74 patients

Purpose of the investigation: To investigate the clinical importance of atypical glandular cells (AGC) on Pap Smear Test (PST). Materials and Methods: Clinical records of 74 patients that were detected with AGC were evaluated. Results: Of the 55 patients detected with AGC-not otherwise specific (AGC-NOS), 42 (76.3%) had negative histopathologic results, eight (14.5%) patients were detected with cervical squamous intraepithelial lesions, one (1.8%) patient was detected with squamous cell cervical cancer, three (5.4%) patients with endometrial hyperplasia, and one (1.8%) patient with endometrial cancer. Of the 19 patients detected with AGC-favor neoplasia (AGC-fn), seven (36.8%) patients had negative histopathologic results, five (26.3%) patients were presented with squamous intraepithelial lesions, one (5.2%) patient was detected with adenocarcinoma in situ, two (10.5%) patients with squamous cell cervical cancer, one patient had complex atypical endometrial hyperplasia, and one (5.8%) patient with endometrial cancer. The incidence of premalignant lesions in the patients with AGC-NOS and AGC-fn was 20% and 36% and the incidence of malignant lesions in the two groups was 3.6% and 26.3%, respectively. Conclusion: Patients detected with AGC on PST should be closely followed up and evaluated by using colposcopy and endocervical and endometrial curettage.

Atypical glandular cells; Pap smear; Management.

[1] Waxman A.G.: “Guidelines for cervical cancer screening: history and scientific rationale”. Clin. Obstet. Gynecol., 2005, 48, 77.

[2] Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M.: “Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008”. Int. J. Cancer, 2010, 127, 2893.

[3] Eser S.Y., ve Karakoç H.: “Cancer Incidence in Turkey”. In: Tuncer M. (ed). Cancer Control in Turkey. Sağlık Bakanlığı Basım Numarası, 2010, 776, 35.

[4] Papanicolaou G.N., Taut H.F.: “The diagnostic value of vaginal smears in carcinoma of the uterus”. Am. J. Obstet. Gynecol., 1941, 42, 193.

[5] Collins L.C., Wang H.H., Abu-Jawdeh G.M.: “Qualifiers of atypical squamous cells of undetermined significance help in patient management”. Mod. Pathol., 1996, 9, 677.

[6] Solomon D., Davey D., Kurman R., Moriarty A., O’Connor D., Prey M., et al.: “The 2001 Bethesda System: terminology for reporting results of cervical cytology”. JAMA, 2002, 287, 2114.

[7] Katki H.A., Schiffman M., Castle P.E., Fetterman B., Poitras N.E., Lorey T., et al.: “Benchmarking CIN 3+ risk as the basis for incorporating HPV and Pap cotesting into cervical screening and management guidelines”. J. Low. Genit. Tract. Dis., 2013, 17, S28.

[8] Meath A.J., Carley M.E., Wilson T.O.: “Atypical glandular cells of undetermined significance. Review of final histologic diagnoses”. J. Reprod. Med., 2002, 47, 249.

[9] Veljovich D.S., Stoler M.H., Andersen W.A., Covell J.L., Rice L.W.: “Atypical glandular cells of undetermined significance: a five-year retrospective histopathologic study”. Am. J. Obstet. Gynecol., 1998, 179, 382.

[10] Daniel A., Barreth D., Schepansky A., Johnson G., Capstick V., Faught W.: “Histologic and clinical significance of atypical glandular cells on pap smears”. Int. J. Gynaecol. Obstet., 2005, 91, 238.

[11] Chan C.W., Cheung K.B.: “Clinical significance and management of cervical atypical glandular cells of undetermined significance”. Hong Kong Med. J., 2003, 9, 346.

[12] Parellada C.I., Schivartche P.L., Pereyra E.A., Chuery A.C., Mioni S.M., Carvalho F.M.: “Atypical glandular cells on cervical smears”. Int. J. Gynaecol. Obstet., 2002, 78, 227.

[13] Chhieng D.C., Elgert P., Cohen J.M., Cangiarella J.F.: “Clinical significance of atypical glandular cells of undetermined significance in postmenopausal women”. Cancer, 2001, 93, 1.

[14] Seok W.I., Lee K.B., Lee J.M., Nam U.G., Yoon S.J., Choi S.L., et al.: “Clinical analysis of atypical glandular cells of undetermined significance (AGUS) on Pap smear according to menopausal status”. Korean J. Obstet. Gynecol., 2002, 45, 967.

[15] Kim S.S., Suh D.S., Kim K.H., Yoon M.S., Choi K.U.: “Clinicopathological significance of atypical glandular cells on Pap smear”. Obstet. Gynecol. Sci., 2013, 56, 76.

[16] Jones B.A., Novis D.A.: “Cervical biopsy-cytology correlation. A College of American Pathologists Q-Probes study of 22 439 correlations in 348 laboratories”. Arch. Pathol. Lab. Med., 1996, 120, 523.

[17] Soofer S.B., Sidawy M.K.: “Atypical glandular cells of undetermined significance: clinically significant lesions and means of patient follow-up”. Cancer, 2000, 90, 207.

[18] Cangiarella J.F., Chhieng D.C.: “Atypical glandular cells—an update”. Diagn. Cytopathol., 2003, 29, 271.

[19] Massad L.S., Einstein M.H., Huh W.K., Katki H.A., Kinney W.K., Schiffman M., et al.: “2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. 2012 ASCCP Consensus Guidelines Conference”. Obstet. Gynecol., 2013, 121, 829.

[20] Sawangsang P., Sae-Teng C., Suprasert P., Srisomboon J., Khunamornpong S., Kietpeerakool C.: “Clinical significance of atypical glandular cells on Pap smears: experience from a region with a high incidence of cervical cancer”. J. Obstet. Gynaecol. Res., 2011, 37, 496.

[21] Westin M.C., Derchain S.F., Rabelo-Santos S.H., Angelo-Andrade L.A., Sarian L.O., Oliveira E., Zeferino L.C.: “Atypical glandular cells and adenocarcinoma in situ according to the Bethesda 2001 classification: cytohistological correlation and clinical implications”. Eur. J. Obstet. Gynecol. Reprod. Biol., 2008, 139, 79.